Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 5Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms 4Sarcoma 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Hodgkin Disease 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Thyroid Carcinoma, Anaplastic 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Seminoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Osteosarcoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × pegfilgrastim × Clear all
NCT02983097 2018-01-19

R²-DHAP

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Phase 1/2 Terminated
34 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡